Wow, they are going to triple their market cap based on "potentially clinically meaningful effects ." Must be nice indeed. I guess their methods or conclusions haven't been attacked - yet.
Madrigal Pharmaceuticals Shares Rise Almost 200% After Company Announced Resmetirom Achieved Both Primary Endpoints in NASH and Liver Fibrosis Trial BENZINGA 7:13 AM ET 12/19/2022
What was their price they sprung up from? 1 yr, 2yr, 3yr high? Nope, just the opposite, almost a 3 yr low.